Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–71 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: albuterol HFA (Proventil HFA) Clear all
Completed Phase 3 Interventional

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

NCT00144846
View directory record Official record
Conditions
Asthma
Interventions
albuterol sulfate inhalation aerosol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 23 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
27
States / cities
Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 7, 2026, 4:06 AM EDT
Not listed Phase 4 Interventional

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

NCT00867737
View directory record Official record
Conditions
Asthma
Interventions
Advair HFA MDI 115/21, Symbicort 160/4.5 pMDI
Drug
Lead sponsor
Allergy and Asthma Center of El Paso
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00909779
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
73
States / cities
Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

NCT00054964
View directory record Official record
Conditions
Asthma
Interventions
Albuterol HFA-BOI, Albuterol HFA-MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 3 Interventional

4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma

NCT00634517
View directory record Official record
Conditions
Asthma
Interventions
Armstrong Albuterol Sulfate Inhalation Aerosol, Albuterol Sulfate Inhalation Aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Stockton, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

NCT00394329
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate, Albuterol sulfate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

NCT00441441
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate, fluticasone propionate/salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Huntington Beach, California • Long Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

NCT00096616
View directory record Official record
Conditions
Asthma
Interventions
Combivent® CFC MDI, Albuterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Lakewood, California • Palmdale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

NCT01899144
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax, ProAir HFA, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Albuterol HFA MDI in Pediatric Participants With Asthma

NCT00577655
View directory record Official record
Conditions
Asthma
Interventions
Albuterol, Placebo, Proventil® HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Huntington Beach, California • Palmdale, California • Paramount, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

NCT03480997
View directory record Official record
Conditions
COPD
Interventions
Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
Combination Product
Lead sponsor
Pneuma Respiratory, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 7, 2026, 4:06 AM EDT
Not listed Phase 3 Interventional

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

NCT03549897
View directory record Official record
Conditions
Asthma
Interventions
Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product
Drug
Lead sponsor
Amneal Ireland Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Brookhaven, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 7, 2026, 4:06 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
3
States / cities
Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

NCT03364608
View directory record Official record
Conditions
Asthma
Interventions
AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

NCT02040779
View directory record Official record
Conditions
Persistent Asthma
Interventions
Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Not applicable Interventional Results available

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes

NCT00521222
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

NCT00685425
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD

NCT00583986
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, COPD
Interventions
Levalbuterol HFA MDI with top mounted actuation indicator
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Encinatas, California • Huntington Beach, California • Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

NCT01479621
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
129
States / cities
Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 7, 2026, 4:06 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

NCT01302587
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
25
States / cities
Glendale, Arizona • Mission Viejo, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 7, 2026, 4:06 AM EDT